GMP-compliant RPE cells show significant rescue of vision in the Royal College of Surgeons (RCS) Rat
LOS ANGELES-- (BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC - News) and the Casey Eye Institute at Oregon Health & Science University initiated a significant collaboration over a year ago that has culminated in a robust study of dosage and efficacy of the GMP-compliant RPE cells. Today at Neuroscience 2007, these researchers are presenting the results of the study using ACT's embryonic stem cell derived RPE cells in the RCS Rat, a well validated animal model of retinal disease. The RPE cells were manufactured under GMP compliant conditions (21CFR211) at the company's facility in Worcester, MA. The RPE cells have been thoroughly characterized and cryo-preserved by the company and were shipped to researchers at OHSU for transplantation. The transplanted rats were given a range of doses of the RPE cells and monitored and evaluated at multiple time points. The results of the study showed that the RPE cells demonstrated a statistically significant therapeutic effect compared to controls with a maximum efficacious effect at a medium dose level. Histological assessment showed integration of the human RPE cells into the rodent's RPE layer without migration into the retina. The conclusions drawn by researchers were that visual function can be rescued and preserved in this animal model of disease utilizing GMP-compliant human ES-derived RPE cells with a functional dose threshold and that these cells may provide an effective donor cell source to rescue photoreceptors in conditions like Age-related macular degeneration (AMD), where RPE function is compromised. Advanced Cell Technology plans to present this data to the FDA when it files an IND for the RPE therapy.
"We are excited by the results of this study which demonstrated the efficacy of our RPE cells in an animal model,” said William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "The data generated by our ongoing collaboration with OHSU represents another milestone in bringing our stem cell therapies from the laboratory to the clinic and ultimately to patients in need of treatment.”
Click to View PDF: GMP-compliant Human RPE Cells Derived from Embryonic Stem Cell Lines Rescue Visual Function In a Rat Model for Photoreceptor Degeneration
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
For more information, visit "www.advancedcell.com":http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Chad Griffin Consulting, Inc.
Jordan Markwith, 310-888-3523
Andrew Hellman, 212-732-4300